Fig. 5.
Fig. 5. PR1-CTLs in peripheral blood of imatinib-treated CML patients. / PR1-CTLs are rarely found in peripheral blood of imatinib-treated CML patients. PR1-CTLs were measured by means of iTAg MHC tetramers (Beckman Coulter). PE-conjugated iTAg MHC tetramers and FITC-labeled CD8-specific monoclonal antibodies (Becton Dickinson) were added to 100 μL whole blood, mixed, and incubated for 30 minutes at room temperature. Erythrocytes were lysed, and the remaining cells were measured on a FACScan (Becton Dickinson). Data were analyzed by means of CellQuest analysis software. Percentages of cells that stain for both CD8 and PR1 are given in the upper right quadrants. The 2 upper plots depict representative PR1-CTL− patients (UPNs 25 and 19) in complete remission under imatinib treatment; 2 lower plots depict 2 PR1-CTL+, IFN-α–treated patients (UPNs 31 and 30) in complete hematological remission.

PR1-CTLs in peripheral blood of imatinib-treated CML patients.

PR1-CTLs are rarely found in peripheral blood of imatinib-treated CML patients. PR1-CTLs were measured by means of iTAg MHC tetramers (Beckman Coulter). PE-conjugated iTAg MHC tetramers and FITC-labeled CD8-specific monoclonal antibodies (Becton Dickinson) were added to 100 μL whole blood, mixed, and incubated for 30 minutes at room temperature. Erythrocytes were lysed, and the remaining cells were measured on a FACScan (Becton Dickinson). Data were analyzed by means of CellQuest analysis software. Percentages of cells that stain for both CD8 and PR1 are given in the upper right quadrants. The 2 upper plots depict representative PR1-CTL− patients (UPNs 25 and 19) in complete remission under imatinib treatment; 2 lower plots depict 2 PR1-CTL+, IFN-α–treated patients (UPNs 31 and 30) in complete hematological remission.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal